Randomized, Double-Blinded, Multicenter, Placebo-Controlled Trial of Shenfu Injection for Treatment of Patients with Chronic Heart Failure during the Acute Phase of Symptom Aggravation (Yang and Qi Deficiency Syndrome)

Table 10

Comparison of incidence of abnormal laboratory indexes between SFI and placebo groups.

Laboratory index	SFI (n=78)	Placebo (n=79)
Blood routine
White blood cell count	12 (16.00%)	9 (11.84%)
Red blood cell count	10 (13.33%)	9 (11.84%)
Hemoglobin	15 (20.00%)	12 (15.79%)
Blood platelet count	11 (14.67%)	8 (10.53%)
Urine routine
Urine protein	6 (11.11%)	10 (16.13%)
Urine sugar	4 (7.41%)	3 (4.84%)
Urine erythrocyte	8 (14.81%)	10 (16.13%)
Urine white blood cell count	11 (20.37%)	8 (12.90%)
Stool routine
Red blood cell	0 (0.00%)	0 (0.00%)
White blood cell	2 (7.14%)	0 (0.00%)
Occult blood	6 (21.43%)	2 (5.13%)
Hepatic and renal function
Alanine transaminase (ALT)	6 (8.45%)	6 (8.57%)
Glutamic oxalacetic transaminase (AST)	7 (9.59%)	5 (6.76%)
Total bilirubin	2 (2.90%)	5 (7.35%)
Urea nitrogen	17 (22.97%)	13 (17.33%)
Creatinine	16 (21.33%)	20 (26.67%)
Electrolytes
K	5 (6.58%)	2 (2.60%)
Na	5 (6.58%)	6 (7.79%)
Cl	3 (3.95%)	5 (6.49%)